🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being described as a "significant breakthrough" in the fight against increasingly resistant strains of the infection, according to researchers.

A Worldwide Public Health Issue

Cases of gonorrhoea are on the rise around the world, with figures suggesting over 82 million infections per year. Particularly high rates are reported in the African continent and nations within the WHO's designated area, which encompasses China and Mongolia to New Zealand. Across England, cases have reached a historical peak, while infection numbers across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary development in the reality of rising global incidence, the spread of superbugs and the very limited available drugs at this time.”

Public health authorities are increasingly worried about the surge in antibiotic-resistant strains. The World Health Organization has listed it as a "priority pathogen". A tracking program found that resistance to standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Drugs Gain Approval

One new antibiotic, alternatively called a brand name, was cleared by the US FDA in mid-December for use against gonorrhoea. This infection can lead to significant complications, including infertility. Experts anticipate that targeted use of this new drug will help hinder the development of resistance.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, was also approved in concurrent days. This treatment, which is employed against urinary tract infections, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin was the result of a unique collaborative effort for medication research. The non-profit organisation GARDP partnered with the drug firm Innoviva to see it through.

“This approval marks a significant shift in the management of multidrug-resistant gonorrhoea, which previously has been staying ahead of antibiotic development.”

Testing Data and Global Access

According to results published in a major medical journal, the new drug cured the vast majority of uncomplicated infections. This establishes an similar efficacy with the typical regimen, which combines a dual-drug approach. The trial enrolled hundreds of volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, GARDP has the rights to make available and distribute the drug in a wide range of low-income and middle-income countries.

Medical professionals directly involved have voiced positive views. Having a one-pill regimen of this kind is seen as a "revolutionary step" for managing the epidemic. This is deemed crucial to reduce the burden of the illness for patients and to prevent the spread of untreatable gonorrhoea globally.